EGFR and lung carcinoma: Treatment with first and second generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, and afatinib, has contributed to therapeutic responses of patients with lung cancer and treatment-naïve oncogenic and activated mutant EGFR (mutEGFR)1–3.